Imricor Medical Systems (ASX:IMR) Long-Term Debt: A$19.97 Mil (As of Dec. 2025)


ASX:IMR Imricor Medical Systems Inc ASX:IMR
47 GF Score
Price A$1.83
GF Value A$0.10
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Imricor Medical Systems Long-Term Debt?

Imricor Medical Systems ASX:IMR -0.82% 47 Long-Term Debt is A$19.97 Mil as of Dec. 2025. GuruFocus rates ASX:IMR with a GF Score™ of 47/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Imricor Medical Systems's Long-Term Debt for the quarter that ended in Dec. 2025 was A$19.97 Mil.

Imricor Medical Systems's quarterly Long-Term Debt increased from Dec. 2024 (A$31.59 Mil) to Jun. 2025 (A$45.02 Mil) but then declined from Jun. 2025 (A$45.02 Mil) to Dec. 2025 (A$19.97 Mil).

Imricor Medical Systems's annual Long-Term Debt increased from Dec. 2023 (A$12.87 Mil) to Dec. 2024 (A$31.59 Mil) but then declined from Dec. 2024 (A$31.59 Mil) to Dec. 2025 (A$19.97 Mil).

Imricor Medical Systems  (ASX:IMR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Imricor Medical Systems Long-Term Debt Related Terms

Imricor Medical Systems Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Imricor Medical Systems's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imricor Medical Systems Long-Term Debt Chart

Imricor Medical Systems Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 3.24 12.87 31.59 19.97

Imricor Medical Systems Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.87 15.69 31.59 45.02 19.97
ASX:IMR
47GF Score
Imricor Medical Systems Inc ASX:IMR
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of A$19.97 Mil mean?
Imricor Medical Systems (ASX:IMR) has a Long-Term Debt of A$19.97 Mil as of Dec. 2025.
Is Imricor Medical Systems' Long-Term Debt too high?
Imricor Medical Systems' current Long-Term Debt is A$19.97 Mil. Overall, Imricor Medical Systems has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' Long-Term Debt compare to ABT and SYK?
Imricor Medical Systems' Long-Term Debt of A$19.97 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Imricor Medical Systems's current Long-Term Debt is A$19.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.83 — trading 1725% above its estimated fair value. The current Long-Term Debt is A$19.97 Mil. Imricor Medical Systems' overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current Long-Term Debt is A$19.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued. The current stock price of A$1.83 is trading 1725% above its estimated GF Value™ of A$0.10. GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.

Key valuation signals for ASX:IMR:

  • Long-Term Debt: A$19.97 Mil
  • GF Value™: A$0.10 vs. price of A$1.83 (1725% above fair value)
  • GF Score™: 47/100 with 10 warning signs

No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imricor Medical Systems Business Description

Address 400 Gateway Boulevard, Burnsville, MN, USA, 55337
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
47GF Score

Get the complete analysis for ASX:IMR

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.83
Price
A$0.10
GF Value